Joanne I. Yeh

Central Taiwan University of Science and Technology — Taiwan

Biochemistry, Genetics and Molecular Biology · Life Sciences

28h-index7.9kcitations87works0.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

RNA modifications and cancer(22), Cytokine Signaling Pathways and Interactions(21), Advanced biosensing and bioanalysis techniques(15), Protein Structure and Dynamics(14), Electrochemical sensors and biosensors(13)

Publications87 total

Function and transcription of the lon gene in Xanthomonas campestris pv. campestris
Antonie van Leeuwenhoek·2025
Supplementary Figure 2 from First-in-Human Trial of a STAT3 Decoy Oligonucleotide in Head and Neck Tumors: Implications for Cancer Therapy
2023Open Access
Supplementary Figure 2 from First-in-Human Trial of a STAT3 Decoy Oligonucleotide in Head and Neck Tumors: Implications for Cancer Therapy
2023Open Access
Supplementary Figure 5 from First-in-Human Trial of a STAT3 Decoy Oligonucleotide in Head and Neck Tumors: Implications for Cancer Therapy
2023Open Access
Supplementary Figure 6 from First-in-Human Trial of a STAT3 Decoy Oligonucleotide in Head and Neck Tumors: Implications for Cancer Therapy
2023Open Access
Supplementary Figure 7 from First-in-Human Trial of a STAT3 Decoy Oligonucleotide in Head and Neck Tumors: Implications for Cancer Therapy
2023Open Access
Supplementary Figure 6 from First-in-Human Trial of a STAT3 Decoy Oligonucleotide in Head and Neck Tumors: Implications for Cancer Therapy
2023Open Access
Supplementary Figure 3 from First-in-Human Trial of a STAT3 Decoy Oligonucleotide in Head and Neck Tumors: Implications for Cancer Therapy
2023Open Access
Supplementary Figure 7 from First-in-Human Trial of a STAT3 Decoy Oligonucleotide in Head and Neck Tumors: Implications for Cancer Therapy
2023Open Access
Supplementary Figure 1 from First-in-Human Trial of a STAT3 Decoy Oligonucleotide in Head and Neck Tumors: Implications for Cancer Therapy
2023Open Access
Supplementary Figure 1 from First-in-Human Trial of a STAT3 Decoy Oligonucleotide in Head and Neck Tumors: Implications for Cancer Therapy
2023Open Access
Supplementary Figure 4 from First-in-Human Trial of a STAT3 Decoy Oligonucleotide in Head and Neck Tumors: Implications for Cancer Therapy
2023Open Access
Supplementary Figure 3 from First-in-Human Trial of a STAT3 Decoy Oligonucleotide in Head and Neck Tumors: Implications for Cancer Therapy
2023Open Access
Supplementary Figure Legends 1-7, Table Legends 1-2 from First-in-Human Trial of a STAT3 Decoy Oligonucleotide in Head and Neck Tumors: Implications for Cancer Therapy
2023Open Access
Supplementary Table 1 from First-in-Human Trial of a STAT3 Decoy Oligonucleotide in Head and Neck Tumors: Implications for Cancer Therapy
2023Open Access
Supplementary Table 2 from First-in-Human Trial of a STAT3 Decoy Oligonucleotide in Head and Neck Tumors: Implications for Cancer Therapy
2023Open Access
Supplementary Table 2 from First-in-Human Trial of a STAT3 Decoy Oligonucleotide in Head and Neck Tumors: Implications for Cancer Therapy
2023Open Access
Supplementary Table 1 from First-in-Human Trial of a STAT3 Decoy Oligonucleotide in Head and Neck Tumors: Implications for Cancer Therapy
2023Open Access
Data from First-in-Human Trial of a STAT3 Decoy Oligonucleotide in Head and Neck Tumors: Implications for Cancer Therapy
2023Open Access
Data from First-in-Human Trial of a STAT3 Decoy Oligonucleotide in Head and Neck Tumors: Implications for Cancer Therapy
2023Open Access
page 1 of 5Next →

Frequent Co-authors

Shoucheng Du(12), Haibin Shi(10), Al Claiborne(6), Tian Xia(4), André E. Nel(4), Ehmke Pohl(4), Daniel E. Koshland(4), John J. Alvarado(4), Thomas E. Smithgall(4), James Luba(3), Gilbert G. Privé(3), Sung‐Hou Kim(3), Unmesh Chinte(3), Adam D. Lazareck(3), Laurie Betts(3), R.D. Kettering(3), Michael Kovochich(2), T. Conn Mallett(2), Edward J. Crane(2), Véronique Charrier(2)